Golden Green’s Immunic IMUX Stock Holding History

Golden Green’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$49K	–	157
2021 Q2	$49K	Hold	400	–	–	0.04%	151
2021 Q1	$64K	Buy	+400	New	+$67.9K	0.06%	162

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Golden Green's IMUX Position: Q2 2022 in Review

Golden Green sold out of Immunic (IMUX) in Q2 2022, closing a stake of 3,265 shares — an estimated $369K sold.

Golden Green first reported a position in IMUX in Q4 2020 and held it in 6 quarters. The position peaked at $1.35M in Q1 2021. 72 funds tracked by Wall St. Rank hold IMUX as of Q2 2022.

Golden Green reported no remaining Immunic position as of Q2 2022 after selling out during the quarter.
Golden Green sold 3,265 Immunic shares in Q2 2022, an estimated $369K.
Golden Green first reported a position in Immunic in Q4 2020 and held it in 6 quarters.
Golden Green's Immunic position peaked at $1.35M in Q1 2021.
72 funds tracked by Wall St. Rank held Immunic as of Q2 2022.

Based on Golden Green's 13F filing for Q2 2022, filed 12 Jul 2022.